Adenoviral conjunctivitis disrupts workplaces, schools, and communities, costing hundreds of millions of dollars annually. With no proven treatment and the potential for rapid spread, vision-threatening complications, and prolonged recovery, employers must take its identification and containment seriously. Meanwhile, this condition frequently presents a diagnostic dilemma, with a wide range of less contagious or treatable conditions masquerading as viral conjunctivitis. This leads to several undesirable scenarios, including the unnecessary furlough of employees who come to work with red eyes and inappropriate prescription of topical antibiotics, which can contribute to antibiotic resistance, to satisfy school, daycare, or workplace guidelines requiring 24 hours of antimicrobial therapy before a student or worker can be cleared to return. Both approaches reflect conventional guidance aimed at trying to limit contagion and absenteeism in a setting of diagnostic uncertainty.1 However, with precise diagnostic tests, such as polymerase chain reaction (PCR) testing, available, it should be possible to distinguish between patients with and without adenoviral conjunctivitis and alleviate much of this uncertainty.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bicket AK, Stein JD. Keeping Red Eyes From Putting Workplaces in the Red. JAMA Ophthalmol. 2021;139(5):524–525. doi:10.1001/jamaophthalmol.2021.0144
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.